Close menu




Cannabis

Photo credits: pixabay.com

Commented by Carsten Mainitz on January 18th, 2022 | 13:07 CET

Ayurcann, Novavax, Covestro - The stragglers are coming!

  • Cannabis

Humanity continues to find itself in the clutches of the Corona pandemic, the infection figures are rising, and the demand from politicians for mandatory vaccination is becoming louder and louder. While BioNTech and Pfizer vaccines and Moderna have dominated to date, new vaccine manufacturers are entering the market in the next wave. The situation is similar in the cannabis industry. After a boom about 3 years ago, the market leaders have since lost up to 80% of their value. Legalization and the rise of Cannabis 3.0. will pave the way for new companies.

Read

Commented by Stefan Feulner on January 12th, 2022 | 12:54 CET

Tilray, Ayurcann, Aurora Cannabis - When will the boom 2.0 come?

  • Cannabis

About five years ago, the boom of cannabis stocks started. Companies like Aurora Cannabis, Canopy Growth and Tilray were able to multiply within a few months. However, the boom was followed by a quick end on the stock market. With corrections of 90% in some cases, the exaggerations were harshly corrected. However, the cannabis market is still in a strong growth phase. The legalization in many countries and the cannabis 3.0 wave promise the companies enormous growth leaps in the next few years. Thus, the steep rise seen at the time could be repeated, at least to some extent.

Read

Commented by Stefan Feulner on December 28th, 2021 | 07:10 CET

Upcoming hydrogen and cannabis boom - Nel ASA, Ayurcann, Canopy Growth

  • Cannabis

These two completely different sectors have one thing in common. After both cannabis stocks and hydrogen sector companies multiplied in the past, a significant correction set in during the stock market year soon ending. This correction is likely to continue into the new year 2022. In the long term, however, there are outstanding opportunities both for cannabis, through legalization in various European countries, and for hydrogen, urgently needed for the energy transition. It is time to position yourself.

Read

Commented by Stefan Feulner on December 23rd, 2021 | 11:15 CET

Novavax, Sativa Wellness Group, Bayer - The next wave ignites

  • Cannabis

There is great concern in society due to the Omicron variant. Reason enough for politicians to further tighten measures, even for the approximately 70% of fully vaccinated people in the Federal Republic. The federal and state governments decided on stricter contact restrictions, large events without spectators and a new vaccination target. By the end of January, a further 30 million booster, first and second vaccinations are to be achieved. As a result, vaccine manufacturers are experiencing another boom. Meanwhile, a new vaccine is coming to Germany to change the minds of vaccination skeptics.

Read

Commented by Armin Schulz on December 20th, 2021 | 13:56 CET

Alibaba, Ayurcann, Rock Tech Lithium - Portfolio boosters for 2022

  • Cannabis

The stock market year 2021 is slowly coming to an end, and many investors have cleaned up their portfolios. The question now is, which trends and stocks will ignite in the coming year! The Corona pandemic has come back into focus with the Omicron variant. So this vexed topic will continue to occupy us in the coming year. Profiteers from this are e-commerce companies like Alibaba. With the new traffic light government, the legalization of cannabis is being tackled. Efforts are increasing worldwide to make the consumption of hemp no longer a criminal offense. Well-positioned in this area is Ayurcann. An exciting third market is lithium, which is essential for the production of electric vehicles. Rock Tech Lithium is excellently positioned in this area.

Read

Commented by Fabian Lorenz on December 14th, 2021 | 12:40 CET

BioNTech, Bayer, Ayurcann: From vaccination records to cannabis

  • Cannabis

The COVID-19 pandemic is dominating the headlines. There is no end in sight to the pandemic. The shares of BioNTech are benefiting from this. The Mainz-based Company has developed the most successful vaccine to date. The blockbuster is likely to remain in demand and generate billions in revenue for BioNTech. Thus, Berenberg sees a price target of USD 400. Health Minister Karl Lauterbach referred to a necessary vaccination rate of over 90% in the ARD program "Anne Will". BioNTech is currently expanding its production capacity. Just like Ayurcann. Because the legalization of cannabis opens the door to a billion-dollar market for the Canadian Company. Bayer also made headlines yesterday - the US Supreme Court is taking a closer look at the glyphosate dispute. That is new food for the gamblers. They have the Bayer share firmly in their grip.

Read

Commented by André Will-Laudien on December 10th, 2021 | 12:54 CET

Daimler, Daimler Trucks, Ayurcann, TUI: Great yield gifts in the Advent season!

  • Cannabis

The so-called quiet time before Christmas is often associated with cozy warmth, gingerbread and mulled wine. At the stock exchange, the books of the large investors close and private investors optimize their capital gains tax by the realization of pending losses. Because from a pure tax point of view, losses from private sales transactions can be set off against profits; only the annual residual profit then has to be taxed. As a result, the autumn stock markets are often more stormy than many people think, and there is less of a sense of "quiet time," according to Christian beliefs. We pick out a few pieces of gingerbread!

Read

Commented by André Will-Laudien on December 9th, 2021 | 13:24 CET

Tilray, Sativa Wellness, NanoRepro, Valneva - The 2022 health winners

  • Cannabis

The topic of cannabis ran through all the gazettes in 2018 and 2019. The Netherlands, Canada and 9 US states were the well-known pioneers in cannabis legalization at the time. It is now also to come in Germany - at least that is what the coalition agreement of the government parties says. The debate about the legalization of cannabis has been going on worldwide for several years. For Germany, the traffic light coalition wants to legalize the controlled distribution to adults for consumption purposes. In this way, they say, licensing the sale of cannabis would also ensure the protection of minors and prevent the spread of contaminated substances. The industry briefly cheered with share price increases but then returned to normal. We take a look at key industry players.

Read

Commented by Stefan Feulner on December 2nd, 2021 | 11:02 CET

Bayer, Ayurcann, JinkoSolar - Excellent prospects

  • Cannabis

"Release the hemp!" cult presenter Stefan Raab called for the legalization of cannabis years ago in a song he produced himself. But not Jamaica, but the traffic light coalition with SPD, FDP and the Greens caused jubilation in the various communities. The release of the drug opens up great opportunities for young companies as well as investors. In contrast to Germany, other countries have already made more progress. Currently, the cannabis sector is in correction mode on the stock market, but the long-term prospects are excellent.

Read

Commented by Carsten Mainitz on November 19th, 2021 | 13:13 CET

Sativa Wellness Group, Aurora Cannabis, TUI - Rising consumer spending on wellness and travel

  • Cannabis

According to Statista, the health and wellness market is worth around EUR 105 billion. More than USD 900 billion is spent annually worldwide on beauty and antiaging alone. Spending on travel is also increasing significantly after a sharp drop in the wake of the Corona pandemic. Reason enough to take a look at three stocks of industry representatives. Who is making the running?

Read